Caleco Pharma Corp. Announces Appointment of Jim Metropoulos MD to Advisory Board
Caleco Pharma Corp. (OTCBB: CAEH)(FRANKFURT: T3R)(WKN: A0N9Y0) (the "Company") is pleased to announce that it has appointed Jim Metropoulos, MD, to the Company's Product Development Advisory Board. The Company's Product Development Advisory Board is responsible for guiding the development of the Company's consumer OTC and prescription products from research stages through commercialization, including the design of appropriate clinical trails and the selection of clinical sites and research partners.
Dr. Metropoulos has served as a senior executive in healthcare communications and product commercialization for over 17 years. Dr. Metropoulos initially served as Chief Strategic Officer for Lowe McAdams Healthcare Worldwide where he was responsible for overseeing the development of comprehensive strategic communications plans for all clients including the integration of Internet, managed care and consumer communications with professional advertising and promotion programs. From 2002 to 2006, Dr. Metropoulos served as Co-President; US Operations for Sudler & Hennessey, a healthcare focused division of the WPP Group. During this time, Dr. Metropoulos was a leader in integrating pre-approval research and post-commercialization observational registries with global communications. Dr. Metropoulos also served as President and CEO of Euro RSCG Life Worldwide a global healthcare communications network and a part of the Havas Group. Dr. Metropoulos is the co-founder of The Rearden Health Partnership, a communications technology, services and media consulting group with offices in New York, New Jersey and Paris. The Partnership designs and develops proprietary communications software platforms for use in education, promotion and product development. Rearden owns and operates private content distribution networks linking healthcare professionals and consumers with healthcare product manufacturers and offers clients a full suite of content development services including advertising, promotional education, internet and managed markets communications.
About Caleco Pharma Corp.
The Company's business plan is to develop its proprietary technology designed to treat moderate to severe liver maladies, including Hepatitis C viral infection, (the "Liver Health Formula") as an over-the-counter medication and as a United States Food and Drug Administration ("FDA") approved pharmaceutical. To date, the Company's intellectual property covering the Liver Health Formula is comprised of patent applications in the United States, Europe and Canada and four European Drug Master File applications.
Caleco Pharma Corp. shares are traded in the United States on the OTC Bulletin Board (OTCBB: CAEH) and in Germany on the Frankfurt Stock Exchange (FRANKFURT: T3R)(WKN: A0N9Y0).
This press release may contain, in addition to historic information, forward-looking statements. These statements may involve known and unknown risks and uncertainties and other factors that may cause the actual results to be materially different from the results implied herein. In particular, there are no assurances that: (i) the United States Patents and Trademarks Office will grant the Company a patent in connection with its current patent applications; (ii) the Company will be able to manufacture and produce its products or that its products will be effective; or (iii) it will be able to carry out any pre-clinical or clinical trials of its products. Readers are cautioned not to place undue reliance on the forward-looking statements made in this press release.
Caleco Pharma Corp.
John Boschert, President
Caleco Pharma Corp.